Amneal Pharmaceuticals, Inc. AMRX
20.14 USD +0.69 (+3.55%)
At closeNov 6, 2026, 5:31 PM EST
20.14 0.00 0.00%
After hours · Nov 6, 5:31 PM ET
19.30 Day range 20.43
11.30 52-week range 21.68
- YTD
- +59.84%
- 1 year
- +72.73%
News
benzinga.com Leerink Partners Maintains Outperform on Amneal Pharmaceuticals, Raises Price Target to $25 Leerink Partners analyst Daniel Clark maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform and raises the price target from $23 to $25.
benzinga.com JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $25 JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $24 to $25.
zacks.com AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance Raised Amneal tops Q3 estimates as strong Affordable Medicines and Specialty growth drives higher 2026 guidance and boosts its growth outlook.
seekingalpha.com Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript
marketbeat.com What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call Amneal Pharmaceuticals NASDAQ: AMRX reported third-quarter 2026 revenue of $863 million, up 10% from a year earlier, as growth in affordable medicines and specialty products more than offset an…
zacks.com Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
benzinga.com Amneal Pharmaceuticals Q3 2026 Earnings Call Transcript Amneal Pharmaceuticals (NASDAQ:AMRX) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
zacks.com Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.17 per share a year ago.
benzinga.com Amneal Pharmaceuticals Raises FY2026 Adj EPS Guidance from $0.96-$1.06 to $1.04-$1.08 vs $1.03 Est; Raises FY2026 Sales Guidance from $3.100B-$3.200B to $3.150B-$3.250B vs $3.159B Est Amneal Pharmaceuticals (NASDAQ:AMRX) raises FY2026 Adj EPS guidance from $0.96-$1.06 to $1.04-$1.08 vs $1.03 analyst estimate. Raises FY2026 sales outlook from $3.100 billion-$3.200 billion to $3.150…
benzinga.com Amneal Pharmaceuticals Q3 Adj. EPS $0.26 Beats $0.23 Estimate, Sales $862.684M Beat $816.058M Estimate Amneal Pharmaceuticals (NASDAQ:AMRX) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.23 by 13.04 percent. This is a 52.94 percent increase over earnings…
globenewswire.com Amneal Reports Third Quarter 2026 Financial Results – Q3 2026 Net Revenue of $863 million ; GAAP Net Loss of $22 million ; Diluted Loss per Share of $(0.06) – – Adjusted EBITDA of $207 million ; Adjusted Diluted EPS of $0.26 – – Updating 2026 Full…
benzinga.com JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $24 JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $22 to $24.- benzinga.com Oppenheimer Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $27 Oppenheimer analyst Les Sulewski initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $27.
benzinga.com Salesforce To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday Wall Street analysts made mixed price-target changes for LYFT, AMRX, JBHT, CRM, APPF, FLNC and CRWD.- benzinga.com Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $20 Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $16 to $20.
benzinga.com Leerink Partners Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $23 Leerink Partners analyst Daniel Clark initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $23.- benzinga.com Amneal Pharmaceuticals Files Prospectus Related To The Offer And Sale Of Up To 28,942,098 Shares of Class A Common Stock By Selling Stockholders https://www.sec.gov/Archives/edgar/data/1723128/000114036126035617/ny20081412x1_s3asr.htm
benzinga.com JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target JP Morgan analyst Chris Schott reinstates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and announces $22 price target.- benzinga.com UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $25 UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $23 to $25.
benzinga.com Amneal Pharmaceuticals Raises FY2026 Adj EPS Guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 Est; Raises FY2026 Sales Guidance from $3.050B-$3.150B to $3.100B-$3.200B vs $3.103B Est Amneal Pharmaceuticals (NASDAQ:AMRX) raises FY2026 Adj EPS guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 analyst estimate. Raises FY2026 sales outlook from $3.050 billion-$3.150 billion to $3.100…
benzinga.com Amneal Pharmaceuticals Q2 Adj. EPS $0.30 Beats $0.22 Estimate, Sales $796.197M Beat $768.206M Estimate Amneal Pharmaceuticals (NASDAQ:AMRX) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.22 by 36.36 percent. This is a 20 percent increase over earnings of…
benzinga.com Two Years to Build or Pay 200% — Which US Pharma Stocks Win? Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.- benzinga.com Amneal Pharma Secures FDA Approval For Additional Strengths And Vial Presentations Of Iohexol Injection; Co. Plans To Launch These Products In Q3 Of 2026 Approval of iohexol injection 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, and 300 mg iodine/mL in 50 mL vial, significantly expands Amneal’s injectable contrast portfolioPortfolio now…
- benzinga.com UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $23 UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $19 to $23.
- benzinga.com Alkermes Terminates VIVITROL Authorized Generic Supply Agreement With Amneal Without Penalties On July 6, 2026, Alkermes plc (the "Company") and Amneal Pharmaceuticals LLC ("Amneal") terminated the previously disclosed Authorized Generic Product Supply Agreement entered into on September 9,…
benzinga.com Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness FDA names seven companies to its PreCheck pilot to speed U.S. drug manufacturing reviews after receiving more than 80 applications.- benzinga.com Zambon And Amneal's Hopledo Receives Positive CHMP Opinion For Parkinson's Disease, European Launch Expected From October 2026 Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more "Good ON" time with fewer daily doses compared with immediate-release…
benzinga.com FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-spray-opioid-overdose
benzinga.com Top 3 Health Care Stocks That May Collapse This Quarter 3 health care stocks flashing warning: CAH RSI 77.7, TGTX RSI 79.8, AMRX RSI 76.9; all overbought, but positive price action for TGTX.- benzinga.com Amneal Pharmaceuticals Announces New Interim Results From Phase 4 Study Reinforcing Reported Benefits Of Parkinson's Treatment Crexont Overall Interim Findings (Entire Study Population, 214Patients; Six-Week Analysis)All 214 patients who switched to CREXONT (mean age 67.1±9.07 years):Increased Daily "Good On" Time:+3.33 hours when…
- benzinga.com Amneal Pharmaceuticals Romidepsin Injection Solution Receives FDA Approval Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's romidepsin injection solution, 27.5…
- benzinga.com Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $16 Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $15 to $16.
benzinga.com Earnings Scheduled For May 1, 2026 
benzinga.com Why Is Amneal Pharmaceuticals Stock Gaining Today? Amneal Pharmaceuticals rises premarket after $1.1B Kashiv BioSciences deal to expand biosimilars platform and tap $300B biologics opportunity, while raising FY26 outlook.- benzinga.com Amneal Pharmaceuticals To Acquire Kashiv BioSciences For $375M In Cash, $375M In Shares Payable Upon Closing And Up To $350M In Potential Payments, Also Reports Preliminary Q1 Sales $723M, Up 4% Yoy, Raises FY2026 Adjusted EPS And Adjusted EBITDA Guidance Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines, today…
- benzinga.com Amneal Pharma Presents New Interim Results From Ongoing Phase 4 ELEVATE-PD Study, At 2026 AAN Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of CREXONT across all prior treatment groupsDemonstrated substantial increases in daily "Good On" time,…
- benzinga.com UBS Initiates Coverage On Amneal Pharmaceuticals with Buy Rating, Announces Price Target of $19 UBS analyst Ashwani Verma initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy rating and announces Price Target of $19.
- benzinga.com FDA Takes Step Forward on Testosterone Therapy for Men https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men
- benzinga.com Earnings Scheduled For February 27, 2026
benzinga.com Earnings Scheduled For October 30, 2025 
benzinga.com Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns.- benzinga.com Earnings Scheduled For August 5, 2025
- benzinga.com NY State Attorney General Letetia James Posts On X "My office and a coalition of AGs secured $720 million from eight pharmaceutical companies for their roles in fueling the opioid epidemic across our nation. We've now secured over $3 billion for New York that will be used to help prevent future devastation from opioids." https://x.com/NewYorkStateAG/status/1943364781936607687
benzinga.com Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris? Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook.- benzinga.com Earnings Scheduled For May 2, 2025
- benzinga.com Earnings Scheduled For February 28, 2025
- benzinga.com Earnings Scheduled For March 1, 2024 Companies Reporting Before The Bell • McEwen Mining (NYSE:MUX) is estimated to report quarterly loss at $0.28 per share on revenue of $71.72 million.
- benzinga.com Earnings Scheduled For November 7, 2023 Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
- benzinga.com Why Asbury Automotive Group Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares climbed 169% to $1.56 after the company announced it selected a lead Alzheimer's drug candidate following proof-of-concept study data.
- benzinga.com General Electric, Verizon, Cleveland-Cliffs And Other Big Stocks Moving Higher On Tuesday U.S. stocks traded higher Tuesday, with the Nasdaq Composite gaining over 100 points. Here are some big stocks recording gains in the trading session.